Optimization of a pyrazolo[1,5-a]pyrimidine class of KDR kinase inhibitors: improvements in physical properties enhance cellular activity and pharmacokinetics
- 14 November 2002
- journal article
- research article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 12 (24), 3537-3541
- https://doi.org/10.1016/s0960-894x(02)00827-2
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- The angiogenic pathway ?vascular endothelial growth factor/flk-1(KDR)-receptor? in rheumatoid arthritis and osteoarthritisThe Journal of Pathology, 2001
- The role of VEGF and thrombospondins in skin angiogenesisJournal of Dermatological Science, 2000
- Angiogenesis in cancer and other diseasesNature, 2000
- Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategyCancer and Metastasis Reviews, 1998
- Patterns and Emerging Mechanisms of the Angiogenic Switch during TumorigenesisCell, 1996
- Vascular Endothelial Growth Factor, a Potent and Selective Angiogenic AgentJournal of Biological Chemistry, 1996
- Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppressionNature Medicine, 1995
- Angiogenesis in cancer, vascular, rheumatoid and other diseaseNature Medicine, 1995
- Synthesis and Secretion of Vascular Permeability Factor/Vascular Endothelial Growth Factor by Human Retinal Pigment Epithelial CellsBiochemical and Biophysical Research Communications, 1993
- Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivoNature, 1993